Back to search

Safety Evaluation of Recombinant Human Interleukin-4

Data up to Jan 2025

Published1997
Citations19
References17

Total Citations Per Year

Abstract

References (17)

Interleukin-4: a prototypic immunoregulatory lymphokine

1991 • 878 citations

Murine interleukin-4 displays potent anti-tumor activity in vivo

1989 • 790 citations

Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4

1991 • 733 citations

An Eosinophil-Dependent Mechanism for the Antitumor Effect of Interleukin-4

1992 • 540 citations

Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.

1992 • 89 citations

Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a phase I dose toxicity trial

1992 • 68 citations

Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma

1994 • 67 citations

A phase II study of subcutaneous recombinant human lnterleukjn-4 in metastatic renal cell carcinoma

1995 • 35 citations

Growth inhibition of human colorectal‐carcinoma cells by interleukin‐4 and expression of functional interleukin‐4 receptors

1994 • 35 citations

Safety Evaluation of Recombinant Human Interleukin-4

1997 • 33 citations

Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model

1995 • 30 citations

Possible Myocardial Toxicity Associated with Interleukin-4 Therapy

1993 • 28 citations

The eosinophil-mediated antitumor activity of interleukin-4

1994 • 27 citations

AN ADENOVIRAL VECTOR EXPRESSING INTERLEUKIN-4 MODULATES TUMORIGENICITY AND INDUCES REGRESSION IN A MURINE BREAST-CANCER MODEL

1995 • 27 citations

IL4 and IL5: The role of two multifunctional cytokines and their place in the network of cytokine interactions

1990 • 15 citations

Intralesional Treatment of Established Murine Primary Renal Tumor With Interleukin-4: Localized Effect on Primary Tumor With no Impact on Metastases

1995 • 11 citations

Recombinant human interleukin 4 (IL-4) sch 39400 in non-small cell lung cancer (NSCLC): Results of a phase II investigation

1994 • 8 citations

Cited By (0)

No citing papers found in database

Safety Evaluation of Recombinant Human Interleukin-4 (1997) – Clinical Immunology and Immunopathology | Metascience Observatory Explorer